Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

[1]  G. Maartens,et al.  Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone , 2020, Antimicrobial Agents and Chemotherapy.

[2]  E. Houpt,et al.  Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis , 2019, Antimicrobial Agents and Chemotherapy.

[3]  K. Dheda,et al.  What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment? , 2019, The Indian journal of medical research.

[4]  K. Dheda,et al.  d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  P. V. van Helden,et al.  Drug‐Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis , 2018, American journal of respiratory and critical care medicine.

[6]  T. Holtz,et al.  Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis , 2018, The Lancet.

[7]  E. V. van Puijenbroek,et al.  Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases , 2018, Drug Safety.

[8]  K. Kimpinski,et al.  Revisiting the Evidence for Neuropathy Caused by Pyridoxine Deficiency and Excess , 2014, Journal of clinical neuromuscular disease.

[9]  K. Bai,et al.  Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  A. Van Rie,et al.  Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[11]  T. Hwang,et al.  Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  Dan J Stein,et al.  The psychometric properties of the K10 and K6 scales in screening for mood and anxiety disorders in the South African Stress and Health study , 2011, International journal of methods in psychiatric research.

[13]  P. Donald.  Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. , 2010, Tuberculosis.

[14]  Alimuddin Zumla,et al.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. , 2010, The Lancet. Infectious diseases.

[15]  R. Holzman,et al.  Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya. , 2010, The American journal of tropical medicine and hygiene.

[16]  Stefan Leucht,et al.  Clinical implications of Brief Psychiatric Rating Scale scores. , 2005, The British journal of psychiatry : the journal of mental science.

[17]  M. Gris,et al.  Pyridoxine in clinical toxicology: a review , 2005, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[18]  James W Mold,et al.  The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. , 2004, The Journal of the American Board of Family Practice.

[19]  D. Katzenstein,et al.  Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels , 2002, AIDS.

[20]  F. Kok,et al.  Alcohol intake assessment: the sober facts. , 1999, American journal of epidemiology.

[21]  K. Dalton,et al.  Characteristics of pyridoxine overdose neuropathy syndrome , 1987, Acta neurologica Scandinavica.

[22]  G. Parry,et al.  Sensory neuropathy with low‐dose pyridoxine , 1985, Neurology.

[23]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[24]  K. I. Fetterhoff,et al.  The role of the cycloserine (seromycin) blood level in the treatment of pulmonary tuberculosis and the prevention and control of cycloserine (seromycin) toxicity. , 1959, Diseases of the chest.

[25]  R. McLean,et al.  Some considerations of cycloserine toxicity. , 1957, American review of tuberculosis.

[26]  I. Kendig,et al.  Psychological side effects induced by cycloserine in the treatment of pulmonary tuberculosis. , 1956, American review of tuberculosis.

[27]  G. A. Brewer,et al.  STRUCTURE AND REACTIONS OF CYCLOSERINE1 , 1955 .

[28]  G. Maartens,et al.  Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  H. Carrara,et al.  Sensory polyneuropathy in human immunodeficiency virus-infected patients receiving tuberculosis treatment. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[30]  J. Heckmann,et al.  Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review [Review article]. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[31]  Simpson et al.  Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels, , 2003 .

[32]  B. Helmy.  Side effects of cycloserine. , 1970, Scandinavian journal of respiratory diseases. Supplementum.

[33]  A PILOT study of cycloserine toxicity; a United States Public Health Service Cooperative Clinical Investigation. , 1956, American review of tuberculosis.